Send us Feedback

Array BioPharma (ARRY)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ARRY » Topics » VentiRx - VTX-2337 & VTX-1463 / Toll-Like Receptor (TLR-8) Program

These excerpts taken from the ARRY 10-K filed Aug 15, 2008.

VentiRx - VTX-2337 & VTX-1463 / Toll-Like Receptor (TLR-8) Program

In February 2007, we entered into a licensing and collaboration agreement with privately held biopharmaceutical company VentiRx, under which we granted VentiRx exclusive worldwide rights to certain molecules from our toll-like receptor, or TLR, program.  The program contains a number of compounds targeting TLR’s to activate innate immunity.  VentiRx expects to develop its first two candidates in cancer and allergy.  We received an equity stake in VentiRx as well

 

7


Table of Contents

 

as an up-front payment, potential milestone payments and royalties on product sales.  We retain an option to acquire a 50 percent ownership position in each VentiRx clinical oncology products developed under this agreement.

 

During fiscal 2008, VentiRx reported the following progress on the program:

 

·                  VentiRx filed an IND application on VTX-2337 for the treatment of cancer, and patients are expected to be enrolled in the Phase I trial during the second half of calendar 2008.

·                  VentiRx advanced VTX-1463 into regulated safety assessment testing for treatment of allergy, with an IND expected to be filed in calendar 2009.

 

During fiscal 2009, we will continue to collaborate with VentiRx on back-up molecules.

 

VentiRx - VTX-2337 & VTX-1463 / Toll-Like Receptor
(TLR-8) Program



In February 2007, we
entered into a licensing and collaboration agreement with privately held
biopharmaceutical company VentiRx, under which we granted VentiRx exclusive
worldwide rights to certain molecules from our toll-like receptor, or TLR,
program.  The program contains a number
of compounds targeting TLR’s to activate innate immunity.  VentiRx expects to develop its first two
candidates in cancer and allergy.  We
received an equity stake in VentiRx as well



 



7















Table
of Contents



 



as an up-front payment,
potential milestone payments and royalties on product sales.  We retain an option to acquire a 50 percent
ownership position in each VentiRx clinical oncology products developed under
this agreement.



 



During fiscal 2008,
VentiRx reported the following progress on the program:



 



·                  VentiRx filed an IND application on VTX-2337 for the treatment of
cancer, and patients are expected to be enrolled in the Phase I trial during the
second half of calendar 2008.



·                  VentiRx advanced VTX-1463 into regulated safety assessment testing for
treatment of allergy, with an IND expected to be filed in calendar 2009.



 



During fiscal 2009, we
will continue to collaborate with VentiRx on back-up molecules.



 



EXCERPTS ON THIS PAGE:

10-K (2 sections)
Aug 15, 2008

RELATED TOPICS for ARRY:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki